KRAS and neoplasm: Primary or intrinsic resistance mechanisms are often associated with the fact that not all KRAS mutant cells depend on KRAS activation to maintain their viability, and this can be maintained despite ablation of the KRAS mutant protein, highlighting the heterogeneity of the different KRAS-mutated tumor cell subclones [159].